Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 3/20 | 1.00 |
| ▸ | GPX4 | P36969 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28479486 | 0.91 | HDAC6 (0.84) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL29608419 | 0.91 | HDAC6 (0.84) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL28470427 | 0.91 | HDAC6 (0.84) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL28476139 | 0.90 | HDAC6 (0.82) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL5775992 | 0.88 | HDAC6 (0.78) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL29609340 | 0.88 | HDAC6 (0.78) | HDAC6HDAC1GPX4TAAR1 | |
| SCHEMBL28614964 | 0.88 | HDAC6 (0.78) | HDAC6HDAC1GPX4TRPV1 | |
| SCHEMBL13627286 | 0.87 | HDAC6 (0.76) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL18688569 | 0.87 | HDAC6 (0.77) | HDAC6HDAC1GPX4TRPV1TAAR1 | |
| SCHEMBL8320157 | 0.85 | HDAC6 (0.74) | HDAC6HDAC1GPX4TRPV1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2004113336-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | HDAC6 11/4885HDAC1 1/4885GPX4 1535/4885 |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | HDAC6 22/4885HDAC1 1/4885GPX4 2696/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | HDAC6 557/4885HDAC1 5/4885GPX4 2437/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | HDAC6 1058/4885HDAC1 9/4885GPX4 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.